You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,697,064


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,697,064
Title:Nitrogenated derivatives of pancratistatin
Abstract: The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well as their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation. ##STR00001##
Inventor(s): Marion; Frederic (Toulouse, FR), Annereau; Jean-Philippe (Toulouse, FR), Fahy; Jacques (Labruguiere, FR)
Assignee: Pierre Fabre Medicament (Boulogne-Billancourt, FR)
Application Number:13/727,101
Patent Claims:1. A method of treating a lung or colon cancer comprising the administration to a person in need thereof of an effective amount of a compound of the following formula (I): ##STR00053## a stereoisomer or a mixture of stereoisomers thereof in all proportions, or a pharmaceutically acceptable salt thereof, in which: R.sub.1 represents a hydrogen atom or a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl or arylalkyl group, R.sub.2 represents a hydrogen atom, a saturated or unsaturated 3- to 7-membered hydrocarbon cycle, a 3- to 7-membered heterocycle or a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, optionally substituted aryl, optionally substituted arylalkyl, C(O)R', SO.sub.2--R', C(O)OR', C(O)NHR', NH.dbd.CNHR', C(.dbd.NR''')R', C(S)R', C(S)OR', or C(S)NHR' group, where R' and R''' represent, independently of each other, a hydrogen atom, a saturated or unsaturated 3- to 7 membered hydrocarbon cycle, an optionally substituted 3- to 7-membered heterocycle, a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, C.sub.1 to C.sub.6 hydroxyalkyl, C.sub.1 to C.sub.6 aminoalkyl, polyamine, polyether, optionally substituted aryl, optionally substituted arylalkyl or optionally substituted heteroaryl group, or R.sub.1 and R.sub.2 form together, with the nitrogen atom bearing them, an optionally substituted heteroaryl or a 3- to 7-membered heterocycle, which can comprise 1 to 3 additional heteroatoms, and optionally substituted with a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl, arylalkyl or heteroaryl group, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent, independently of each other, a hydrogen atom, a saturated or unsaturated 3- to 7-membered hydrocarbon cycle or a SO.sub.3H, PO.sub.3H.sub.2, C(O)OH, C(O)R'', C(O)OR'', C(O)NHR'', C(S)R'', C(S)OR'', C(S)NHR'' group, where R'' represents a hydrogen atom; a saturated or unsaturated 3- to 7-membered hydrocarbon cycle; a 3- to 7-membered heterocycle optionally substituted with a linear or branched C.sub.1 to C.sub.6 alkyl; a linear or branched C.sub.1 to C.sub.6 alkyl; linear or branched C.sub.2 to C.sub.6 alkenyl; linear or branched C.sub.2 to C.sub.6 alkynyl; C.sub.I to C.sub.6 hydroxyalkyl; C.sub.1 to C.sub.6 aminoalkyl; optionally substituted polyamine; polyether; optionally substituted aryl; or optionally substituted heteroaryl group, or R.sub.3 and R.sub.4 together form a --CR.sub.8R.sub.9--, --SO.sub.2-- or --PO.sub.2H-- chain binding the oxygen atoms bearing them, wherein R.sub.8 and R.sub.9 represent, independently of each other, a hydrogen atom or a linear or branched C.sub.1 to C.sub.6 alkyl group, and R.sub.7 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl or linear or branched C.sub.2 to C.sub.6 alkynyl group or a saturated or unsaturated 3- to 7-membered hydrocarbon cycle.

2. The method according to claim 1, wherein the mixture of stereoisomers is a mixture of enantiomers.

3. The method of claim 2, wherein the mixture of enantiomers is a racemate mixture.

4. The method wherein the compound of formula (I) meets the following formula (Ia): ##STR00054## for which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined in claim 1.

5. The method according to claim 1, wherein R.sub.1 represents a hydrogen atom.

6. The method according to claim 1, wherein R.sub.2 represents a group --C(O)R' with R' representing an aryl group optionally substituted.

7. The method according to claim 1, wherein R.sub.2 represents a group --C(O)R' with R' representing a phenyl group optionally substituted.

8. The method according to claim 1, wherein R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 each represent a hydrogen atom.

9. The method according to claim 1, wherein R.sub.8 and R.sub.9 represent, independently of each other, a hydrogen atom or a methyl group.

10. The method according to claim 1, wherein the compound of formula (I) is chosen among the following compounds: ##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062##

11. A method of treating a lung or colon cancer comprising the administration to a person in need thereof of an effective amount of a pharmaceutical composition comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable excipient.

12. The method according to claim 11, wherein the pharmaceutical composition comprises at least one other active principle chosen from among anti-cancer agents including 6-mercaptopurine, fludarabine, cladribine, pentostatin, cytarabine, 5-fluorouracile, gemcitabine, methotrexate, raltitrexed, irinotecan, topotecan, etoposide, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, mitoxantrone, chlormethine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, busulfan, carmustine, fotemustine, streptozocin, carboplatin, cisplatin, oxaliplatin, procarbazine, dacarbazine, bleomycin, vinblastine, vincristine, vindesine, vinorelbine, paclitaxel, docetaxel, L-asparaginase, flutamide, nilutamide, bicalutamide, cyproterone acetate, triptorelin, leuprorelin, goserelin, buserelin, formestane, aminoglutethimide, anastrozole, letrozole, tamoxifen, octreotide and lanreotide.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.